Patients with Invasive Lobular Carcinoma Show a Significant Increase in IRS-4 Expression Compared to Infiltrative Ductal Carcinoma-A Histopathological Study

Medicina (Kaunas). 2022 May 28;58(6):722. doi: 10.3390/medicina58060722.

Abstract

Background and Objectives: Breast cancer (BC) is the first diagnosed type of cancer and the second leading cause of cancer-related mortality in women. In addition, despite the improvement in treatment and survival in these patients, the global prevalence and incidence of this cancer are rising, and its mortality may be different according to the histological subtype. Invasive lobular carcinoma (ILC) is less common but entails a poorer prognosis than infiltrative ductal carcinoma (IDC), exhibiting a different clinical and histopathological profile. Deepening study on the molecular profile of both types of cancer may be of great aid to understand the carcinogenesis and progression of BC. In this sense, the aim of the present study was to explore the histological expression of Insulin receptor substrate 4 (IRS-4), cyclooxygenase 2 (COX-2), Cyclin D1 and retinoblastoma protein 1 (Rb1) in patients with ILC and IDC. Patients and Methods: Thus, breast tissue samples from 45 patients with ILC and from 45 subjects with IDC were analyzed in our study. Results: Interestingly, we observed that IRS-4, COX-2, Rb1 and Cyclin D1 were overexpressed in patients with ILC in comparison to IDC. Conclusions: These results may indicate a differential molecular profile between both types of tumors, which may explain the clinical differences among ILC and IDC. Further studies are warranted in order to shed light onto the molecular and translational implications of these components, also aiding to develop a possible targeted therapy to improve the clinical management of these patients.

Keywords: breast cancer (BC); cyclin D1; cyclooxygenase 2 (COX-2); insulin receptor substrate 4 (IRS-4); invasive lobular carcinoma (ILC); retinoblastoma protein 1 (Rb1).

Publication types

  • Comparative Study

MeSH terms

  • Breast Neoplasms* / drug therapy
  • Breast Neoplasms* / genetics
  • Carcinoma, Ductal, Breast* / diagnosis
  • Carcinoma, Ductal, Breast* / drug therapy
  • Carcinoma, Ductal, Breast* / genetics
  • Carcinoma, Lobular* / pathology
  • Cyclin D1 / therapeutic use
  • Cyclooxygenase 2
  • Female
  • Humans
  • Insulin Receptor Substrate Proteins / genetics

Substances

  • IRS4 protein, human
  • Insulin Receptor Substrate Proteins
  • Cyclin D1
  • Cyclooxygenase 2